[1] FDA. Guidance for industry: patient-reported outcome mea?
sures: use in medical product development to support labeling
claims: draft guidance[J].Health Quality of Life Outcomes,
2006(4):79-99.
[2] 杨洁,白文瑾,张岩波.基于关节炎患者报告结局量表的条目筛
选[J].中国药物与临床,2012,12(12):1529-1532.
[3] 张岩波.潜变量分析[M].北京:高等教育出版社,2009,5:94-98.
[4] 万崇华,黄新萍,常巍,等.患者报告的临床结局研究述评[J].郑州大学学报:医学版,2011,46(4):501-505.
[5] Burckhardt CS. The impact of arthritis on quality of life[J].
Nursing Research,1985,1(34):11-17.
[6] 王洁晶,唐晓颇,姜泉,等.类风湿关节炎患者报告结局量表应用
效果评价[J].世界中西医结合杂志,2014,9(11):1193-1196.
[7] Meenan RF, Mason JH, Anderson JJ,et al. The content and
properties of a revised and expanded arthritis impact measure?
ment scales health status questionnaire[J].Arthritis Rheu?
matism,1992,35(1):1-10.
[8] Bellamy N, Buchanan WW, Goldsmith CH,et al. Validation
study of WOMAC: a health status instrument for measuring
clinically important patient relevant outcomes to anti-rheumat?
ic drug therapy in patients with osteoarthritis of the hip or knee
[J].J Rheumatol,1988(15):1833-1840.
[9] Stucki G, Meier D, Stucki S,et al. Evaluation of a German
version of WOMAC (Western Ontario and McMaster Univer?
sities)Arthrosis Index[J].Z Rheumatol,1996,55(1):40-49.